Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome?
Cumulative evidence suggests that metabolic syndrome (MetS) may be important in the development of mild cognitive impairment, vascular dementia, and Alzheimer's disease (AD). As such, these patients might be described as having "metabolic-cognitive syndrome"--MetS plus cognitive impairment of degenerative or vascular origin. While peripheral insulin resistance appears to be of primary pathophysiological importance in MetS, the definitions of MetS and its components do not include any reference to insulin resistance or hyperinsulinemia. In the present article, we discuss the role of these factors in the development of cognitive decline and dementia, including underlying mechanisms that influence amyloid-beta (Abeta) peptide metabolism and tau protein hyperphosphorylation, the principal neuropathological hallmarks of AD. In AD, an age-related desynchronization of biological systems results, involving stress components, cortisol and noradrenaline, reactive oxygen species, and membrane damage as major candidates that precipitates an insulin resistant brain state (IRBS) with decreased glucose/energy metabolism and the increased formation of hyperphosphorylated tau protein and Abeta. Unfortunately, it is very difficult to include the measurement of peripheral insulin resistance in the current MetS criteria or the identification of IRBS for the metabolic-cognitive syndrome. However, since inflammation has been suggested among the MetS components, we propose IRBS as an additional feature of the metabolic-cognitive syndrome to also identify a molecular profile in patients at high risk of developing predementia or dementia syndromes.
Frisardi
Vincenza
V
Department of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Italy.
Solfrizzi
Vincenzo
V
Capurso
Cristiano
C
Imbimbo
Bruno P
BP
Vendemiale
Gianluigi
G
Seripa
Davide
D
Pilotto
Alberto
A
Panza
Francesco
F
D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000503:physiopathology*; D001928:Brain Diseases, Metabolic / Q000150:complications / Q000209:etiology / Q000473:pathology*; D003072:Cognition Disorders / Q000150:complications / Q000209:etiology / Q000473:pathology*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D008954:Models, Biological
D016229:Amyloid beta-Peptides